Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
0.68
0.05 (7.59%)
At close: Sep 05, 2025, 3:59 PM
0.70
2.90%
After-hours: Sep 05, 2025, 07:43 PM EDT
Company Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States.
It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.
The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Iterum Therapeutics
| Country | IE |
| IPO Date | May 25, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Corey N. Fishman |
Contact Details
Address: Fitzwilliam Court Dublin, IE | |
| Website | https://www.iterumtx.com |
Stock Details
| Ticker Symbol | ITRM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001659323 |
| CUSIP Number | G6333L101 |
| ISIN Number | IE000TTOOBX0 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Corey N. Fishman | President, Chief Executive Officer & Director |
| Judith M. Matthews | Chief Financial Officer |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director |
| Dr. Steven I. Aronin M.D. | Senior Vice President & Head of Clinical Development |
| Louise Barrett | Senior Vice President of Legal Affairs & Secretary |
| Tom Loughman Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 28, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 4 | Filing |
| Aug 05, 2025 | 10-Q | Quarterly Report |
| Aug 05, 2025 | 8-K | Current Report |
| Aug 04, 2025 | 8-K | Current Report |
| Jul 29, 2025 | DEF 14A | Filing |
| Jul 18, 2025 | 8-K | Current Report |
| Jul 18, 2025 | PRE 14A | Filing |
| Jul 03, 2025 | 4 | Filing |